Trials / Not Yet Recruiting
Not Yet RecruitingNCT06359509
Study of SYS6020 in BCMA-positive Multiple Myeloma
A Phase І Study of BCMA-targeted Chimeric Antigen Receptor T Cell (SYS6020) Injection in Relapsed or Refractory Multiple Myeloma
- Status
- Not Yet Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multi-center, phase I trial that studies the efficacy and recommended dose of BCMA CART cells in treating patients with BCMA-positive multiple myeloma (MM) that have not respond or relapsed after chemotherapy. B-cell maturation antigen (BCMA), a cell surface protein expressed on malignant plasma cell, has emerged as a very selective antigen to be targeted in novel immunotherapy for MM.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | BCMA Targeted CAR T-cells | Each patient will receive BCMA Targeted CAR T-cells by intravenous infusion. |
Timeline
- Start date
- 2024-04-01
- Primary completion
- 2027-05-01
- Completion
- 2032-05-01
- First posted
- 2024-04-11
- Last updated
- 2024-04-11
Source: ClinicalTrials.gov record NCT06359509. Inclusion in this directory is not an endorsement.